.Pharmacolibrary.Drugs.ATC.L.L01XX67 .Pharmacolibrary.Drugs.ATC.L.L01XX67| name: | Tagraxofusp |
| ATC code: | L01XX67 | route: | intravenous |
| n-compartments | 2 |
Tagraxofusp (SL-401) is a fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp is approved for adult and pediatric patients 2 years and older with BPDCN.
Pharmacokinetics in adult patients with BPDCN, after intravenous infusion. Values primarily reflect population PK analyses from clinical studies.